Is the small heat shock protein αB-crystallin an oncogene?

Journal of Clinical Investigation

Volumn 116, Issue 1, 2006, Pages 30-32

  Gruvberger Saal, Sofia K ^a   Parsons, Ramon ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CRYSTALLIN; HEAT SHOCK PROTEIN; ONCOPROTEIN; TUMOR MARKER;

BREAST CANCER; CANCER CLASSIFICATION; CARCINOGENICITY; DISEASE MARKER; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW;

ALPHA-CRYSTALLIN B CHAIN; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 31044436397     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27462     Document Type: Review

References (29)

1. Clark, J.I., and Muchowski, P.J. 2000. Small heat-shock proteins and their potential role in human disease. Curr. Opin. Struct. Biol. 10:52-59.
2. Parcellier, A., et al. 2005. Small heat shock proteins HSP27 and alphaB-crystallin: cytoprotective and oncogenic functions. Antioxid. Redox Signal. 7:404-413.
3. Sun, Y., and MacRae, T.H. 2005. The small heat shock proteins and their role in human disease. FEBS J. 272:2613-2627.
4. Aoyama, A., et al. 1993. Expression of alpha B-crystallin in human brain tumors. Int. J. Cancer. 55:760-764.
5. Pinder, S.E., et al. 1994. The expression of alpha B-crystallin in epithelial tumours: a useful tumour marker? J. Pathol. 174:209-215.
6. Sorlie, T., et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98:10869-10874.
7. Chelouche-Lev, D., Kluger, H.M., Berger, A.J., Rimm, D.L., and Price, J.E. 2004. alphaB-crystallin as a marker of lymph node involvement in breast carcinoma. Cancer. 100:2543-2548.
8. Wulfkuhle, J.D., et al. 2002. Proteomics of human breast ductal carcinoma in situ. Cancer Res. 62:6740-6749.
9. Moyano, J.V., et al. 2006. αB-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J. Clin. Invest. 116:261-270. doi:10.1172/JCI25888.
10. Zhou, Q., et al. 2000. Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. Breast Cancer Res. Treat. 59:27-39.
11. Ciardiello, F., et al. 1992. Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-alpha genes on in vitro transformation of human mammary epithelial cells. Mol. Carcinog. 6:43-52.
12. Miller, F.R., Pauley, R.J., and Wang, B. 1996. Activated c-Ha-ras is not sufficient to produce the preneoplastic phenotype of human breast cell line MCF10AT. Anticancer Res. 16:1765-1769.
13. Li, D.W., et al. 2005. Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alphaB-crystallin through inhibition of RAS activation. Mol. Biol. Cell. 16:4437-4453.
14. Chen, Z., et al. 2001. MAP kinases. Chem. Rev. 101:2449-2476.
15. Moll, R., Franke, W.W., Schiller, D.L., Geiger, B., and Krepler, R. 1982. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:11-24.
16. Moll, R., Krepler, R., and Franke, W.W. 1983. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation. 23:256-269.
17. Dairkee, S.H., Mayall, B.H., Smith, H.S., and Hackett, A.J. 1987. Monoclonal marker that predicts early recurrence of breast cancer [letter]. Lancet. 1:514.
18. Perou, C.M., et al. 2000. Molecular portraits of human breast tumours. Nature. 406:747-752.
19. Sorlie, T., et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 100:8418-8423.
20. Sotiriou, C., et al. 2003. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 100:10393-10398.
21. van de Rijn, M., et al. 2002. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am. J. Pathol. 161:1991-1996.
22. Nielsen, T.O., et al. 2004. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10:5367-5374.
23. Arnes, J.B., et al. 2005. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin. Cancer Res. 11:4003-4011.
24. Ross, D.T., and Perou, C.M. 2001. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis. Markers. 17:99-109.
25. Charafe-Jauffret, E., et al. 2006. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. In press.
26. Makretsov, N.A., et al. 2004. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin. Cancer Res. 10:6143-6151.
27. Wittig, R., et al. 2002. Candidate genes for crossresistance against DNA-damaging drugs. Cancer Res. 62:6698-6705.
28. Rouzier, R., et al. 2005. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11:5678-5685.
29. Rinehart, J., et al. 2004. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22:4456-4462.